Building on these positive outcomes, eight clinical trials are underway or planned to assess the therapeutic effect of SKB264, alone or in combination with other agents, in multiple advanced solid tumors, such as NSCLC, TNBC, and HR+/HER2- BC. The gene discussed is ERBB2; the disease is breast cancer.